Key terms
About TARA
Protara Therapeutics, Inc. is a clinical-stage company engaged in developing treatments for rare and specialty diseases with significant unmet needs. Its current development programs focus on the treatment of rare diseases in structural and connective tissues and rare hepatology, gastrointestinal, and metabolic disorders. The company was founded by Jesse Shefferman and Jacqueline Zummo in March 2006 and is headquartered in New York, NY.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest TARA news
Apr 08
6:15am ET
Buy Rating for Protara Therapeutics’ TARA-002 Based on Promising Clinical Data and Market Potential in NMIBC Treatment
Apr 05
8:32am ET
Protara Therapeutics Launches $45M Private Placement Drive
Apr 05
8:19am ET
Protara Therapeutics announces $45M private placement financing
Apr 05
8:14am ET
Protara Therapeutics announces three-month data from TARA-002 program
Apr 05
8:05am ET
Protara announces alignment with FDA on path forward for IV Choline Chloride
Mar 18
5:32pm ET
Protara Therapeutics CMO Resigns, Interim Successor Named
Mar 14
6:30am ET
Analysts Conflicted on These Healthcare Names: Cadrenal Therapeutics, Inc. (CVKD), Protara Therapeutics (TARA) and Spruce Biosciences (SPRB)
Mar 13
12:05pm ET
Buy Rating on Protara Therapeutics Backed by Promising TARA-002 Clinical Trials and Significant Market Opportunity
Mar 13
8:02am ET
Protara Therapeutics expects cash to fud operations into 2Q25
Mar 13
8:02am ET
Protara Therapeutics reports Q4 EPS (90c), consensus (92c)
No recent press releases are available for TARA
TARA Financials
Key terms
Ad Feedback
TARA Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
TARA Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
